The COVID-19 pandemic has impacted every business and there are many unanswered occupational health questions related to monitoring the COVID-19 health status of workers in order to guide return to work decisions. Since ACOEM’s last webinar (April 24) on COVID-19
serology, new research and policy on serology test quality and application to return-to-work issues is already available.
Dr. Whitman will present findings from a University of California (UC) San Francisco/UC Berkeley/Massachusetts General Hospital study comparing sensitivity and specificity across 12 different serologic tests and discuss the effect of sample timing after symptoms
on test sensitivity.
Dr. Gronvall will discuss a national strategy for serologic testing, developed by the Center for Health Security at the Johns Hopkins University, and focus on return-to-work applications. These presentations will be followed by a live, moderated Q&A.
An additional panel member, Dr. Theel, will address questions on emerging serologic tests, differences between COVID-19 serologic test quality, and the application of serologic tests on return to work issues.
Test Performance Evaluation of 12 SARS-CoV-2 Serology Assays
Jeffrey Whitman, MD, MS, Department of Laboratory Medicine, University of California, San Francisco
A National Strategy for COVID-19 Serology Testing
Gigi Gronvall, PhD, Associate Professor and Senior Scholar, Center for Health Security, Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health.
Questions on the Application of COVID-19 Serologic Tests to Return to Work
Elitza Theel, PhD, Director, Infectious Disease Serology Laboratory; Associate Professor, Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.